Table 4.

Clinical associations of repeat polymorphisms.

	IR1 perfect repeats versus degraded			Kaposin B/C open reading frames versus loss
	n = 16			n = 38a
	OR	(95 per cent CI)	P	OR	(95 per centCI)	P
Age, per 5 years	1.17	(0.86, 1.60)	0.31	1.12	(0.84, 1.48)	0.44
Female versus male	0.47	(0.03, 6.41)	0.57	2.88	(0.56, 14.75)	0.21
HIV-positive versus HIV-negative	0.22	(0, 3.0)	0.13d	2.37	(0.22, 25.95)	0.48
CD4+ cell count, per 100/ul	0.99	(0.34, 2.94)	0.99	0.85	(0.66, 1.09)	0.20
HIV viral load (log10 copies/ml), per unitb	0.50	(0.01, 23.66)	0.72	0.79	(0.15, 4.12)	0.78
Plasma KSHV (log10 copies/ml), per unitc	0.98	(0.16, 6.07)	0.98	1.20	(0.44, 3.31)	0.72
No. of body sites w/lesions, per site	0.98	(0.59, 1.63)	0.93	1.19	(0.87, 1.62)	0.28
Any head, neck, or oral lesions	0.67	(0.08, 5.48)	0.71	4.33	(0.94, 19.98)	0.06
Any nodular lesions	2.14	(0.16, 29.46)	0.57	0.96	(0.18, 5.17)	0.97
KS T-stage 1	1.25	(0.08, 19.25)	0.87	0.68	(0.12, 4.03)	0.68
KS S-stage 1	7.50	(0.57, 98.37)	0.13	0.82	(0.20, 3.46)	0.79
KS I-stage 1 b	0.67	(0.06, 7.50)	0.74	0.64	(0.16, 2.54)	0.52

^aIncludes six individuals in a concurrent whole-genome sequencing study and sixteen from an earlier study (Rose et al. 2018), all from the HIPPOS cohort.

^bHIV+ only.

^cAmong those with measured plasma KSHV RNA.

^dExact logistic regression.